These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 34504980)

  • 1. Estimation of the censoring distribution in clinical trials.
    Jiang S; Swanson D; Betensky RA
    Contemp Clin Trials Commun; 2021 Sep; 23():100842. PubMed ID: 34504980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Estimation of colorectal adenoma recurrence with dependent censoring.
    Hsu CH; Long Q; Alberts DS
    BMC Med Res Methodol; 2009 Sep; 9():66. PubMed ID: 19788750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonparametric estimation in an illness-death model with component-wise censoring.
    Eaton A; Sun Y; Neaton J; Luo X
    Biometrics; 2022 Sep; 78(3):1168-1180. PubMed ID: 33914913
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the estimation of intracluster correlation for time-to-event outcomes in cluster randomized trials.
    Kalia S; Klar N; Donner A
    Stat Med; 2016 Dec; 35(30):5551-5560. PubMed ID: 27790737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Measures of follow-up in time-to-event studies: Why provide them and what should they be?
    Betensky RA
    Clin Trials; 2015 Aug; 12(4):403-8. PubMed ID: 26025565
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copula graphic estimation of the survival function with dependent censoring and its application to analysis of pancreatic cancer clinical trial.
    Jo JH; Gao Z; Jung I; Song SY; Ridder G; Moon HR
    Stat Methods Med Res; 2023 May; 32(5):944-962. PubMed ID: 36919342
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GRADE Guidelines: 29. Rating the certainty in time-to-event outcomes-Study limitations due to censoring of participants with missing data in intervention studies.
    Goldkuhle M; Bender R; Akl EA; van Dalen EC; Nevitt S; Mustafa RA; Guyatt GH; Trivella M; Djulbegovic B; Schünemann H; Cinquini M; Kreuzberger N; Skoetz N;
    J Clin Epidemiol; 2021 Jan; 129():126-137. PubMed ID: 33007458
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin.
    Kawahara T; Shinozaki T; Matsuyama Y
    BMC Med Res Methodol; 2020 Jul; 20(1):204. PubMed ID: 32736528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Informative censoring of surrogate end-point data in phase 3 oncology trials.
    Gilboa S; Pras Y; Mataraso A; Bomze D; Markel G; Meirson T
    Eur J Cancer; 2021 Aug; 153():190-202. PubMed ID: 34186504
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Censored patients in Kaplan-Meier plots of cancer drugs: An empirical analysis of data sharing.
    Rosen K; Prasad V; Chen EY
    Eur J Cancer; 2020 Dec; 141():152-161. PubMed ID: 33160265
    [TBL] [Abstract][Full Text] [Related]  

  • 12. General independent censoring in event-driven trials with staggered entry.
    Rühl J; Beyersmann J; Friedrich S
    Biometrics; 2023 Sep; 79(3):1737-1748. PubMed ID: 35762259
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Causal inference for long-term survival in randomised trials with treatment switching: Should re-censoring be applied when estimating counterfactual survival times?
    Latimer NR; White IR; Abrams KR; Siebert U
    Stat Methods Med Res; 2019 Aug; 28(8):2475-2493. PubMed ID: 29940824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correcting for dependent censoring in routine outcome monitoring data by applying the inverse probability censoring weighted estimator.
    Willems S; Schat A; van Noorden MS; Fiocco M
    Stat Methods Med Res; 2018 Feb; 27(2):323-335. PubMed ID: 26988930
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A note on competing risks in survival data analysis.
    Satagopan JM; Ben-Porat L; Berwick M; Robson M; Kutler D; Auerbach AD
    Br J Cancer; 2004 Oct; 91(7):1229-35. PubMed ID: 15305188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Addressing an idiosyncrasy in estimating survival curves using double sampling in the presence of self-selected right censoring.
    Frangakis CE; Rubin DB
    Biometrics; 2001 Jun; 57(2):333-42. PubMed ID: 11414553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Impact of informative censoring on the Kaplan-Meier estimate of progression-free survival in phase II clinical trials.
    Campigotto F; Weller E
    J Clin Oncol; 2014 Sep; 32(27):3068-74. PubMed ID: 25113767
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An analytic method for randomized trials with informative censoring: Part II.
    Robins JM
    Lifetime Data Anal; 1995; 1(4):417-34. PubMed ID: 9385113
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The importance of censoring in competing risks analysis of the subdistribution hazard.
    Donoghoe MW; Gebski V
    BMC Med Res Methodol; 2017 Apr; 17(1):52. PubMed ID: 28376736
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Administrative and artificial censoring in censored regression models.
    Joffe MM
    Stat Med; 2001 Aug; 20(15):2287-304. PubMed ID: 11468764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.